In view of the association of PTGIS with a poor clinical outcome of ovarian cancer, targeting PGI2 synthesis either directly, or indirectly via COX inhibition, may be a promising option to improve the treatment of HGSC patients. The gene discussed is PTGIS; the disease is ovarian cancer.